Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AMPD2 | Q01433 | 3/20 | 0.38 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | MPO | P05164 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL52723 | 0.99 | AMPD2 (0.37) | AMPD2NCF1ALDH1A1L3MBTL1HDAC1 | |
| SCHEMBL51385 | 0.85 | AMPD2 (0.37) | AMPD2NCF1ALDH1A1L3MBTL1MPO | |
| SCHEMBL52326 | 0.76 | FFAR4 (0.38) | AMPD2HDAC1HDAC6 | |
| SCHEMBL12215851 | 0.71 | CRY1 (0.39) | NCF1ALDH1A1L3MBTL1P2RX7 | |
| SCHEMBL29817889 | 0.71 | ALDH1A1 (0.59) | NCF1ALDH1A1L3MBTL1MPO | |
| Hydrochloric Acid SCHEMBL2528915 | 0.70 | CRY1 (0.39) | NCF1ALDH1A1L3MBTL1P2RX7 | |
| SCHEMBL12215772 | 0.66 | CA1 (0.40) | — | |
| Hydrochloric Acid SCHEMBL2531492 | 0.65 | CA1 (0.39) | ALDH1A1 | |
| SCHEMBL52688 | 0.65 | P2RX7 (0.41) | ALDH1A1L3MBTL1P2RX7 | |
| Hydrochloric Acid SCHEMBL2531529 | 0.64 | P2RX7 (0.40) | ALDH1A1L3MBTL1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2280981-B1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-04-23 | — | — | EP | disclosed |
| US-8129398-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253677-A1 | HIV Integrase Inhibitors | DNTT, POLB, UNG | AMPD2 797/4885NCF1 1037/4885ALDH1A1 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.